Aegerion Pharmaceuticals, Inc. (AEGR)
-NasdaqGS 60.11 
1.46(2.37%) 4:00PM EDT|After Hours
:
60.11 0.00 (0.00%) 4:23PM EDT
| Prev Close: | 61.57 |
|---|
| Open: | 61.71 |
|---|
| Bid: | 59.90 x 500 |
|---|
| Ask: | 62.50 x 1500 |
|---|
| 1y Target Est: | 60.67 |
|---|
| Beta: | 0.68 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 59.90 - 62.21 |
|---|
| 52wk Range: | 12.87 - 63.72 |
|---|
| Volume: | 545,044 |
|---|
| Avg Vol (3m): | 625,914 |
|---|
| Market Cap: | 1.73B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.71 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Too Many Questions Make This Thursday Mover a Sellat Motley Fool(Mon 8:36AM EDT)
- The Best- And Worst- Performing Biotech Stocks, May 10 To May 17at Forbes(Sun, May 19)
- 3 Humongous Health-Care Stocks This Weekat Motley Fool(Sat, May 18)
- 4 Companies With Extreme Price Charts And High Statistical Probability Of Declineat Seeking Alpha(Fri, May 17)
- AEGERION PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Aegerion Stock Falls On Unusually High Volume (AEGR)at TheStreet(Fri, May 17)
- Presentation Pandemonium Equals 30% Popat Motley Fool(Fri, May 17)
- Aegerion price target raised to $65 from $50 at Leerinktheflyonthewall.com(Fri, May 17)
- Thursday’s movers: Berkshire hit by S&P downgradeat MarketWatch(Thu, May 16)
- Aegerion surges after bullish projection on Juxtapid potentialat theflyonthewall.com(Thu, May 16)
- U.S. Stock Options With Biggest Changes in Implied Volatilityat Bloomberg(Thu, May 16)
- 4 Stocks Improving Performance Of The Health Care Sectorat TheStreet(Thu, May 16)
- 3 Stocks Near 52-Week Highs Worth Sellingat Motley Fool(Thu, May 16)
- Six longs in a resilient marketat MarketWatch(Wed, May 15)
- How one bull is staying in AegerionoptionMONSTER(Tue, May 14)
Key Statistics
| Forward P/E (1 yr): | 273.23 |
|---|
| P/S (ttm): | 1,441.42 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.29 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.63 |
|---|
| Mean Recommendation*: | 1.4 |
|---|
| PEG Ratio (5 yr expected): | 0.42 |
|---|
Business Summary
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases in the United States.
View More